PLH 2301
Alternative Names: PLH-2301Latest Information Update: 24 Apr 2026
At a glance
- Originator Pluto
- Class
- Mechanism of Action 5-lipoxygenase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sarcopenia
Most Recent Events
- 11 Feb 2026 Pluto Inc plans a phase II trial for Sarcopenia (In elderly) in South Korea (PO) in February 2026 (NCT07390552)
- 06 Feb 2026 Preclinical trials in Sarcopenia in South Korea (PO) before February 2026